Various Workwear Styles for a Professional Appearance with Style and Safety
In the workplace, presentation is crucial. Your...
ShiraTronics Secures $66M to Advance Novel Therapy for Migraine
ShiraTronics Secures $66M to Advance Novel Therapy for MigraineMedTech startup ShiraTronics has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday. Co-founded in 2018 by Mudit Jain, Ph. D., CEO and partner at Treo Ventures and Lynn Elliott, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines.
Please login to comment on this Post